Taris' TAR-302 reduces daily incontinence episodes by 75% in Phase Ib

Taris Biomedical LLC (Lexington, Mass.) reported Phase Ib data in August showing that TAR-302 reduced mean daily incontinence episodes by 75% at day 42 in idiopathic overactive bladder (OAB) patients who were experiencing an average of more than five daily urge incontinence episodes. TAR-302 was well tolerated.

TAR-302 comprises a drug-device combination using the company's Taris system to deliver a controlled-release dosage of the antimuscarinic agent trospium into the bladder. The open-label, U.S. trial enrolled 11 patients with idiopathic OAB refractory to oral therapy to receive TAR-302, which was placed into the bladder through an inserter and continuously released trospium until its removal at day 42...